Trial Profile
A Phase II Study of BIBF1120 in Recurrent and Platinum-Sensitive Small Cell Lung Cancer (SCLC)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 19 Jul 2022
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 04 Jul 2016 Status changed from not yet recruiting to withdrawn prior to enrolment due to contract issues.
- 07 Jul 2014 New trial record